Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial

MLA

Haitao Yin, et al. “Raltitrexed versus 5‐fluorouracil with Cisplatin and Concurrent Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: An Open Labeled, Randomized, Controlled, and Multicenter Clinical Trial.” Cancer Medicine, vol. 9, no. 17, Sept. 2020, pp. 6166–72. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae5c4ba121f5f0634f94e8b5a29f1199&authtype=sso&custid=ns315887.

APA

Haitao Yin, Xia He, Wen-Jie Guo, Buhai Wang, Hongping Zhou, Dan Song, Fuzheng Zhang, Chong Zhou, Ning Jiang, Pengwei Yan, Xuesong Jiang, Feijiang Wang, Shengfu Huang, Xiuhua Bian, Xiangdong Sun, Juying Liu, Li Yin, Jianfeng Wu, & Feng Li. (2020). Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial. Cancer Medicine, 9(17), 6166–6172.

Chicago

Haitao Yin, Xia He, Wen-Jie Guo, Buhai Wang, Hongping Zhou, Dan Song, Fuzheng Zhang, et al. 2020. “Raltitrexed versus 5‐fluorouracil with Cisplatin and Concurrent Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: An Open Labeled, Randomized, Controlled, and Multicenter Clinical Trial.” Cancer Medicine 9 (17): 6166–72. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae5c4ba121f5f0634f94e8b5a29f1199&authtype=sso&custid=ns315887.